With the continuous economic development, the increase of clinically applicable symptoms of products, and the growth of the aging population, more patients are able to use blood products, and the demand for domestic blood products will maintain a steady growth.
It is learned that Hebei Daan Pharmaceutical Co., Ltd. (hereinafter referred to as: Daan Pharmaceutical) has received a strategic investment of RMB 1.122 billion The financing was invested by Lhasa Shengtai (hereinafter referred to as Lhasa Shengtai), a wholly-owned holding company of Junzheng Group Company, and accounted for 31.17% of the registered capital of Daan Pharmaceutical after the capital increase and share expansion.
According to the announcement issued by the Junzheng Group, the evaluation / valuation of Da’an Pharmaceutical has not yet been determined. The tentative valuation of Da’an Pharmaceutical in this transaction is 2.1 billion yuan, corresponding to approximately 35.29 times Daan Pharmaceutical’s 2018 net profit; The valuation of Daan Pharmaceutical after the completion of the previous capital increase is approximately 1.939 billion yuan.
In addition, the net profit of Daan Pharmaceutical in the first three quarters of 2019 was RMB 13,911.8 million, which was a big drop from the RMB 59,499,300 in the whole year of 2018. Some analysts pointed out that Daan Pharmaceuticals faces the risk of a significant decline in operating performance throughout the year.
Daan Pharmaceutical’s shareholding structure
According to the announcement, Daan Pharmaceuticals is mainly engaged in the production and sale of blood products. It can produce human blood albumin, human immunoglobulin, tetanus human immunoglobulin and rabies patient immunoglobulin and other blood products. Has strong comprehensive utilization of plasma and R & D sales capabilities. The increase in capital of Lhasa Shengtai, which is based on the chemical industry, in Daan Pharmaceutical is a cross-industry investment.
In addition, its major shareholder Bohui Bio is a high-tech biomedical enterprise integrating R & D, production, sales and after-sales service. It has formed molecular diagnostics, immunodiagnostics, atomic Five major technology platforms for absorption, atomic fluorescence and mass spectrometry, of which human trace element detection systems have been widely used in more than 7,000 hospitals across the country, with an annual detection volume of 22 million; in addition, its blood product base is also a perennial Production of blood products.
From the company’s official website
Blood products are strategic materials related to national economy and people’s livelihood. They are not only the key medicines for treating many acute and severe diseases, but also the necessary materials for rescuing the wounded during the war.
In this regard, the Junzheng Group stated that the qualification of the blood products industry is scarce, the barriers to entry are high, and the supervision is strict; and with the continuous economic development, the increase of clinically applicable symptoms of products, and the growth of the aging population, More patients have the ability to use blood products, and domestic demand for blood products will maintain steady growth.